- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02407977
Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy
October 19, 2018 updated by: Duke University
This is an observational study.
This protocol will determine the feasibility of using a novel nano-material based fiber-optic dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time, pin-point, in-vivo radiation dose given during external beam delivery of radiation therapy treatments.This new protocol is similiar in design to Pro00050297 with the significant difference being the monitoring will be performed during external baem radiotherapy.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The device is currently in use in an ongoing IRB approved protocol Pro00050297 "Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy".
Brachytherapy is an integral part of the management of many gynecological cancers, which uses radioactive isotopes to deliver radiation treatment in close proximity to the target.
The protocol uses the device in the setting of gynecologic brachytherapy to monitor real time doses, with a primary endpoint of feasibility and accuracy.
Accrual is ongoing, however, the device has initially given consistent results, within 3% of the expected values.
This initial experience is intentionally designed with the simplest geometry and positioning.
This protocol has a similar design to the initial brachytherapy trial, but with the significant difference that the monitoring will be performed during external beam radiotherapy.
Calibration procedures are different in this scenario, and the considerations of when and where dose monitoring will be useful are distinct from these considerations in brachytherapy.
Study Type
Observational
Enrollment (Actual)
13
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medica Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Subjects with histologically documented neoplasm of the pelvis (including gynecologic, gastrointestinal, and genitourinary origin).
Description
Inclusion Criteria:
- Histologically documented neoplasm of the pelvis (including gynecologic, gastrointestinal, and genitourinary origin).
- Planned external beam radiotherapy as part of standard of care treatment
- The radiotherapy plan involves the body surface
- Age > 18 years
- Able to provide and execute informed consent
Exclusion Criteria:
- Allergy or previous intolerance of skin adhesives
- Any clinical scenario in which the nanoFOD placement or reading would compromise the treatment efficacy, or endanger the patient in any way.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dosimetric accuracy of the device with reference to a commercially available dosimeter
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.
Time Frame: 24 months
|
Feasibility in this context will mean ease of clinical use (subjective) and lack of device failures.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Junzo Chino, MD, Duke Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 13, 2015
Primary Completion (Actual)
April 19, 2017
Study Completion (Actual)
April 19, 2017
Study Registration Dates
First Submitted
March 31, 2015
First Submitted That Met QC Criteria
March 31, 2015
First Posted (Estimate)
April 3, 2015
Study Record Updates
Last Update Posted (Actual)
October 22, 2018
Last Update Submitted That Met QC Criteria
October 19, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- Pro00061601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer of the Gastrointestinal, Genitourinary or Gynecologic Systems
-
M.D. Anderson Cancer CenterEdwards LifesciencesCompletedLiver Diseases | Gastrointestinal Diseases | Kidney Diseases | Esophageal Diseases | Prostate Cancer | Pancreatic Diseases | Gynecologic Diseases | Spinal Disease | Disorder of the Genitourinary SystemUnited States
-
IGF Oncology, LLCCompletedMelanoma | Breast Cancer | Brain Cancer | Head and Neck Cancers | Gastrointestinal Cancers | Gynecologic Cancers | Genitourinary Cancers | Thoracic CancersUnited States
-
Virginia Commonwealth UniversityCompletedSarcoma | Breast Cancer | Gynecologic Cancer | Gastrointestinal Cancer | Genitourinary CancerUnited States
-
Dana-Farber Cancer InstituteEnrolling by invitationBreast Cancer | Gynecologic Cancer | Thoracic Cancer | Gastrointestinal Cancer | Genitourinary CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedLeukemia | Breast Cancer | Gynecologic Cancer | Lung Cancer | Skin Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Endocrine Cancer | Male Genital CancerUnited States
-
Per PfeifferCompletedFirst-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus orDenmark
-
Centre Hospitalier Universitaire DijonTerminatedNon-resectable Metastatic Cancer of the Lung | Non-resectable Metastatic Cancer of the Colon | Non-resectable Metastatic Cancer of the Rectosigmoid Junction | Non-resectable Metastatic Cancer of the Stomach | Non-resectable Metastatic Cancer of the Bile Duct | Non-resectable Metastatic Cancer... and other conditionsFrance
-
Fox Chase Cancer CenterAstraZenecaCompletedCancer of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Cancer of the StomachUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); ECOG-ACRIN Cancer Research GroupWithdrawnGastrointestinal Cancer | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Adenocarcinoma of the Esophagus | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric... and other conditionsUnited States
-
AGO Study GroupEssex Pharma GmbH; MedServ. GmbH, WiesbadenCompletedCervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian TumoursGermany
Clinical Trials on Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Cervix, Cancer of the EndometriumUnited States